| ID | 1231 |
| Name of the vaccine | ACAM-CDIFF |
| Microbe | Bacteria |
| Disease name | Clostridium Difficile Infection |
| Name of bacteria | Clostridium difficile |
| Type of vaccine | Toxoid |
| Nucleic acid content | Linear DNA |
| Age | 18 to 85 years |
| Description of the vaccine | Clostridium Difficile toxoid vaccine. |
| Name of the manufacturer | Sanofi Pasteur, a Sanofi Company |
| Name of the manufacturing country | United Kingdom, United States |
| Year of manufacture | 2012 |
| Clinical Phase status | Clinical - Phase 2 |
| Bacterial strain | Gram-positive bacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Three doses of 0.5 mL on days 0, 7, and 28. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | With or without adjuvant |
| Repurposing | For diarrhoea. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination (3 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT00772343 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|